Results 71 to 80 of about 77,151 (268)
Diagnosing Systemic Mastocytosis: State of the Art
International Journal of Laboratory Hematology, EarlyView.ABSTRACT With the advent of effective multikinase and selective tyrosine kinase inhibitors in systemic mastocytosis, diagnosing this rare disease has been critical to improving patient morbidity and mortality. This state‐of‐the‐art review interprets the international diagnostic criteria, including differences between the WHO 5th edition classification ...
Anton Rets, Tracy I. George
wiley +1 more source
Kounis Syndrome Associated With Selective Anaphylaxis to Cefazolin. [PDF]
, 2018 info:eu-repo/semantics ...
Chambel, M +5 more
core +1 more source
Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review
Pediatric Dermatology, EarlyView.ABSTRACT We report an 11‐month‐old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off‐label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of ...
Janis Chang +3 more
wiley +1 more source
Equine Veterinary Education, Volume 38, Issue 2, Page 101-108, February 2026.Summary Background Endoscopy, including tracheal mucus score (TMS) and bronchoalveolar lavage (BAL) fluid cytology, is commonly employed in the diagnosis of equine asthma (EA). Large‐scale studies comparing clinical signs, TMS and BAL cytology are warranted.
M. Larsen +5 more
wiley +1 more source
Clinical features of mastocytosis at pediatric patients
Vestnik Dermatologii i Venerologii, 2017 Mastocytosis is relevant to heterogeneous disease group characterized with redundant accumulation and proliferation of mast cells in tissues. The skin form of mastocytosis is mainly occurs in children.
D. V. Proshutinskaya, O. S. Makoveckaya
doaj +1 more source
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. [PDF]
PLoS ONE, 2011 Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms ...
Daniela Silva Moura +10 more
doaj +1 more source
Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway [PDF]
, 2018 Mutations in KIT and TET2 are associated with myeloid malignancies. We show that loss of TET2-induced PI3K activation and -increased proliferation is rescued by targeting the p110α/δ subunits of PI3K.
Gerbaulet, A +13 more
core +1 more source
Immunology, Volume 177, Issue 2, Page 355-369, February 2026.(A) Proposed model for Abl1 degradation via Nbeal2. Nbeal2 interacts with Abl1 with its WDR domain. This results in proteasomal degradation by a yet unidentified ubiquitin ligase. Therefore, Nbeal2 inactivation stabilises Abl1, which supports mast cell (MC) degeneration. (B) In wt MCs, the Abl1 protein level is controlled by Nbeal2. Furthermore, Nbeal2
Raphaela Marquardt +10 more
wiley +1 more source
Cutaneous mastocytosis: Clinical Case
Педиатрическая фармакологияSkin syndrome is common in the practice of allergologist-immunologist, and it requires differential diagnosis. One of the rare skin diseases among children is mastocytosis caused by excessive accumulation of mast cells in various organs.
Aset Kh. Ibisheva +5 more
doaj +1 more source
CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas
American Journal of Hematology, Volume 101, Issue 1, Page 110-128, January 2026.ABSTRACT The tumor necrosis factor (TNF)‐receptor superfamily 8 receptor CD30 molecule is expressed in all tumor cells of Hodgkin lymphoma and anaplastic large cell lymphoma but is only weakly expressed in a small subset of large lymphoid cells in normal peripheral lymphoid tissues.
Harald Stein, Brunangelo Falini
wiley +1 more source